TAIO PHAR 
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 325B 2.08B | Sales 2025 * | 335B 2.14B | Capitalization | 611B 3.91B |
|---|---|---|---|---|---|
| Net income 2024 * | 14.4B 92.22M | Net income 2025 * | 20.6B 132M | EV / Sales 2024 * | 1.88 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.82 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 8,784 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.83% | 4 M€ | +2.14% | ||
| 0.79% | 19 M€ | +11.55% | ||
| 0.19% | 1,083 M€ | +4.70% |
Taisho Pharmaceutical Holdings Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and sale of over-the-counter drugs, quasi-drugs, foods, medical supplies, hygiene products, and ethical drugs. The Company operates in two business segments. The Self-Medication segment is engaged in the research, development, manufacture and sale of over-the-counter drugs, quasi-drugs, foods, medical supplies, hygiene products. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of ethical drugs. The other business is engaged in the leasing and management of real estate, as well as hotel management business.
Sector
-
Calendar
2024-07-31
- Q1 2024 Earnings Release (Projected)